Phase I study of combination treatment with PTK 787/ZK 222584 (PTK/ZK) and cetuximab for patients with advanced solid tumors: Safety, pharmacokinetics, pharmacodynamics, and toxicity analysis

被引：0
|
作者：
Langenberg, M. H. [1 ,2 ,3 ]
Witteveen, P. O. [1 ,2 ,3 ]
Lankheet, N. [1 ,2 ,3 ]
Roodhart, J. M. [1 ,2 ,3 ]
Rosing, H. [1 ,2 ,3 ]
Beijnen, J. H. [1 ,2 ,3 ]
Voest, E. E. [1 ,2 ,3 ]
机构：
[1] Univ Med Ctr Utrecht, Utrecht, Netherlands
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Slotervaart Hosp, Amsterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2575
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase I/II trial of single-agent PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM)
    Yung, W. K. Alfred
    Friedman, H.
    Reardon, D.
    Provenzale, J.
    Jackson, E.
    Serajuddin, H.
    Laurent, D.
    Chen, B.
    Conrad, C.
    ANNALS OF ONCOLOGY, 2004, 15 : 207 - 207
  • [22] A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a multi-VEGF receptor tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme
    Resardon, David
    Friedman, H.
    Brada, M.
    Conrad, C.
    Provenzaie, J.
    Jackson, E.
    Serajuddin, H.
    Chen, B.
    Laurent, D.
    Yung, W.
    ANNALS OF ONCOLOGY, 2004, 15 : 207 - 207
  • [23] A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer
    Thomas, A. L.
    Trarbach, T.
    Bartel, C.
    Laurent, D.
    Henry, A.
    Poethig, M.
    Wang, J.
    Masson, E.
    Steward, W.
    Vanhoefer, U.
    Wiedenmann, B.
    ANNALS OF ONCOLOGY, 2007, 18 (04) : 782 - 788
  • [24] Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC)
    Pavel, M. E.
    Bartel, C.
    Heuck, F.
    Neumann, F.
    Tiling, N.
    Pape, U. F.
    Ploeckinger, U.
    Wiedenmann, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a multi-VEGF receptor tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM)
    Reardon, D
    Friedman, H
    Brada, N
    Conrad, C
    Provenzale, J
    Jackson, E
    Serajuddin, H
    Chen, B
    NEURO-ONCOLOGY, 2004, 6 (04) : 381 - 381
  • [26] A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (Pts) with stage IC to IV epithelial ovarian cancer (EOC).
    Schroder, W.
    Campone, M.
    Abadie, S.
    Witteveen, P.
    Viens, P.
    Jalava, T.
    Palacay-Radona, M.
    Bilic, S.
    Laurent, D.
    Du Bois, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 274S - 274S
  • [27] Antiangiogeness as new treatment modality in ovarian cancer: a phase lb, open label, safety and pharmacokinetics (PK) study of escalating doses of PTK787/ZK222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (pts) with stage IC to IV epithelial ovarian cancer
    Schroeder, W.
    Abadie, S.
    Witteveen, P. O.
    Campone, M.
    Viens, P.
    Jalava, T.
    Masson, E.
    Bilic, S.
    Chlistalla, A.
    du Bois, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 273 - 273
  • [28] EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma
    Brandes, Alba A.
    Stupp, Roger
    Hau, Peter
    Lacombe, Denis
    Gorlia, Thierry
    Tosoni, Alicia
    Mirimanoff, Rene O.
    Kros, Johan M.
    van den Bent, Martin J.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (02) : 348 - 354
  • [29] A phase I study of the VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK 222584) and gemcitabine in patients with advanced pancreatic cancer.
    Kuo, T.
    Fitzgerald, A.
    Kaiser, H.
    Sikic, B. I.
    Fisher, G. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 208S - 208S
  • [30] Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (Pts) with unresectable hepatocellular carcinoma (HCC).
    Koch, I
    Baron, A
    Roberts, S
    Junker, U
    Palacay-Ramona, M
    Masson, E
    Kay, A
    Wiedenmann, B
    Laurent, D
    Cebon, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 341S - 341S
12345